CollPlant Ends AbbVie Partnership, Halves Staff to Extend Cash Runway to Q4 2026
CollPlant terminated its five-year dermal and soft tissue filler agreement with AbbVie and is seeking new aesthetic partnerships. The company is cutting about 50% of its workforce to extend cash runway into Q4 2026 and advance regenerative aesthetics, breast implants and 3D bioprinting bioinks.
1. AbbVie Agreement Termination
CollPlant ended its five-year development partnership with Allergan Industrie SAS (AbbVie), terminating its dermal and soft tissue filler program upon 60 days’ notice and positioning the company to pursue fresh collaborations in the aesthetics sector.
2. Workforce Reduction and Cash Runway
The company launched a cost-reduction plan to cut approximately 50% of its workforce, update its expense forecast and extend its cash runway into Q4 2026, aiming to focus resources on strategic growth areas.
3. Strategic Core Programs
CollPlant is advancing three flagship programs—photocurable regenerative dermal and soft tissue fillers, regenerative breast implants and rhCollagen BioFlex inks for 3D bioprinting—and is in active discussions with Tier 1 corporations to initiate clinical trials within two years.
4. Bioinks Portfolio and U.S. Expansion
The newly launched BioFlex rhCollagen kit for DLP 3D bioprinting supports advanced tissue modeling and organ fabrication, while a cGMP-compliant U.S. logistics hub now enables expanded North American distribution of rhCollagen and BioInk products.